Plasma pharmacokinetics of N-[2-(dimethylaminolethyl]acridine-4- carboxamide in a phase I trial

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 1, 1999, Pages 45-50

  Kestell, Philip ^a   Dunlop, Ingrid C ^a   McCrystal, Michael R ^b   Evans, Barrie D ^b   Paxton, James W ^c   Gamage, Ranjith S K A ^c   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Amsacrine; Clinical trial 1 Acid glycoprotein; DACA; Topoisomerase

Indexed keywords

ACRIDINE DERIVATIVE; AMSACRINE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; OROSOMUCOID;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID TUMOR;

ACRIDINES; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0033056717     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050943     Document Type: Article

References (25)

1. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA (1987) Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carbox-amide. J Med Chem 30: 664-669
2. Baguley BC, Zhuang L, Marshall E (1995) Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol 36: 244-248
3. Bono JS de, Propper D, Ellard S, Steiner J, Bevan P, Dobbs N, Flannigan E, Ganesan TS, Talbot DC, Campbell S, Twelves C, Harris A (1998) A phase I study of XR5000 (DACA) by 120 hour intravenous infusion. Proceedings, 10th NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam, June 16-18
4. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73-80
5. Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC, Davey MW (1997) The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemother Pharmacol 39: 424-430
6. EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23: 1083-1087
7. Evans SMH, Young D, Robertson IGC, Paxton JW (1992) Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. Cancer Chemother Pharmacol 31: 32-36
8. Evans SMH, Robertson IGC, Paxton JW (1994) Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. J Pharm Pharmacol 46: 63-67
9. Finlay GJ, Marshall ES, Matthews JHL, Paull KD, Baguley BC (1993) In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31: 401-406
10. Finlay GJ, Riou J-F, Baguley BC (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine 4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 32A: 708-714
11. Fuse E, Kobayashi S, Inaba M, Suzuki H, Sugiyama Y (1994) Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J Natl Cancer Inst 86: 989-996
12. Gibaldi M, Perrier D (eds) (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
13. Graham MA, Kaye SB (1993) New approaches in preclinical and clinical pharmacokinetics. Cancer Surv 17: 27-50
14. Harley CB, Kim NW (1996) Telomerase and cancer. In: De Vita VT, Helman S, Rosenberg SA (eds) Important advances in oncology. Lippencott-Raven, Philiadelphia, pp 57-67
15. Holford NHG (1985) MKMODEL, a modelling tool for microcomputers - a pharmacokinetic evaluation and comparison with standard computer programs. Clin Exp Pharmacol [Suppl] 9: 95
16. Jurlina JL, Varcoe R, Paxton JW (1985) The pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. Cancer Chemother Pharmacol 14: 21-25
17. Kestell P, Paxton JW, Evans PC, Young D, Jurlina JL, Robertson IGC, Baguley BC (1990) Disposition of amsacrine and its analogue 9-((2-methoxy-4-[(methylsulfonyl)-amino] phenyl)amino)-N,5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Cancer Res 50: 503-508
18. McCrystal MR, Evans BD, Harvey VJ, Thompson PI, Porter DJ, Baguley BC (1999) Phase I study of the cytotoxic agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Cancer Chemother Pharmacol (in press)
19. Paxton JW, Hardy JR, Evans PC, Harvey VJ, Baguley BC (1988) The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4-acridine carboxamide (CI-921) in a phase I trial. Cancer Chemother Pharmacol 22: 235-240
20. Paxton JW, Young D, Evans SM, Kestell P, Robertson IG, Cornford EM (1992) Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother Pharmacol 29: 379-384
21. Paxton JW, Young D, Robertson IGC (1993) Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans. Cancer Chemother Pharmacol 32: 323-325
22. Raveendran R, Heybroek WM, Caulfield M, Abrams SML, Wrigley PFM, Slevin M, Turner P (1992) Protein binding of indomethacin, methotrexate and morphine in patients with cancer. Int J Clin Pharmacol Res 12: 117-122
23. Schneider E, Darkin SJ, Lawson PA, Ching L-M, Ralph RK, Baguley BC (1988) Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Eur J Cancer Clin Oncol 24: 1783-1790
24. Schofield PC, Robertson IGC, Paxton JW, Gamage RSKA, McCrystal MR, Evans BD, Kestell P, Baguley BC (1999) Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) in cancer patients undergoing a phase I clinical trial. Cancer Chemother Pharmacol 44: 51-58
25. Young D, Evans PC, Paxton JW (1990) Quantitation of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high-performance liquid chromatography. J Chromatogr 528: 385-394